HER2-HER3 Dimerization | QF-Pro Glossary

View

Definition

HER2-HER3 heterodimers form the most potent mitogenic signaling unit in the ErbB receptor family. HER3 lacks kinase activity but provides docking sites for PI3K pathway activation when dimerized with HER2. FRET-based detection of active HER2-HER3 dimers could identify patients with functional receptor engagement even at HER2-low expression levels.

Video Segments

HER2/EGFR/HER3 Interactions in HNSCC

Primary

Most mitogenic dimer

Strongest growth signal

Pathway activation

HER3 recruits PI3K

HER2-low opportunity

IHC 1+/2+ patients

FRET-detectable

Dimerization at binding distance

The Signaling Powerhouse

The ErbB receptor family includes four members: EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). HER2 has no known ligand but is the preferred dimerization partner for all other family members.

HER3 is unique: it has a non-functional kinase domain and cannot signal alone. However, HER3 contains six docking sites for the p85 subunit of PI3K–more than any other receptor. When HER3 dimerizes with the constitutively active kinase HER2, the result is the most potent mitogenic signaling unit in the family.

HER2-HER3 heterodimers drive cell proliferation, survival, and therapy resistance through robust PI3K/Akt pathwayLoading... activation. This biology explains why HER2-targeted therapies (trastuzumab, pertuzumab) that disrupt dimerization are clinically effective.

Simplified

Why HER3 Matters: HER2 is the famous breast cancer target, but it doesn't work alone. HER2 pairs with HER3, which provides the docking sites for PI3K—the signal that drives cancer growth.

Current Testing Gap: We test for HER2 expression/amplification but not HER2/HER3 interaction. This may miss patients with active signaling despite "low" HER2.

The HER2-Low Opportunity

Current HER2 testing uses IHCLoading... and FISH to classify tumors as HER2-positive (IHC 3+ or FISH-amplified) or HER2-negative. HER2-targeted therapies have traditionally been restricted to HER2-positive patients.

However, the emergence of antibody-drug conjugates (trastuzumab deruxtecan) has expanded interest in "HER2-low" tumors–those scoring IHC 1+ or 2+/FISH-negative. These patients may have sufficient HER2 expression for ADC targeting even without "positive" classification.

FRET-based detection of HER2-HER3 dimerization offers a functional alternative to expression-based thresholds. A tumor with low HER2 expression but active HER2-HER3 dimerization may be more biologically dependent on HER2 signaling than a tumor with high expression but low dimerization.

Measuring dimerization state could identify patients who would benefit from HER2-targeted therapy despite failing traditional expression criteria–expanding the eligible population based on functional biology.

Simplified

Emerging Category: "HER2-low" breast cancer is now recognized as a distinct category, with new drugs (T-DXd) showing benefit.

The Question: Among HER2-low patients, which have active HER2/HER3 signaling? Functional measurement could identify them and potentially expand therapy eligibility.

QF-Pro Application

Exploratory

Theoretical Application: HER2/HER3 heterodimerization represents a compelling target for QF-Pro development. HER3 provides PI3K-binding sites that drive downstream Akt activation–the pathway already validated by FRET in breast cancer.

QF-Pro's two-site labeling approach could measure HER2/HER3 proximity at the 1-10nm range indicative of genuine receptor complex formation–potentially expanding therapy eligibility for "HER2-low" patients with active signaling.

Status: Theoretical application pending clinical validation studies.

Note: This represents a theoretical application based on validated QF-Pro principles. Clinical validation studies are pending. See QF-Pro Applications for validated targets.

Simplified

Future potential: HER2/HER3 dimerization drives the Akt pathway (already validated by FRET). Measuring actual receptor pairing could identify "HER2-low" patients with active signaling who might benefit from HER2-targeted therapy.

HER2 Expression Threshold

IHC 3+ or FISH+ ' Treat
Expression-based eligibility
Misses low-expression/high-function patients

HER2-HER3 Dimerization

Active heterodimer ' Treat
Function-based eligibility
Captures oncogenic dependence

Clinical Opportunities

HER2-low expansion: ~55% of breast cancers are HER2-low (IHCLoading... 1+ or 2+/FISH-); dimerization-based stratification could identify optimal candidates for ADC therapy
Resistance mechanisms: HER3 upregulation is a known resistance mechanism to HER2-targeted therapy; monitoring HER2-HER3 dimerization could detect emerging resistance
Combination therapy: Pertuzumab specifically blocks HER2-HER3 dimerization; functional biomarkersLoading... could identify patients most likely to benefit from pertuzumab-containing regimens
Beyond breast cancerLoading...: HER2 signaling drives subsets of gastric, colorectal, and other cancers; dimerization-based stratification could expand therapeutic indications

Connected Terms

EGFR Category Cross-ref Related Learning Path Video
PKB/Akt Category Related Learning Path
Breast Cancer Cross-ref Related
FRET Cross-ref Related
Functional Biomarkers Cross-ref Related
PI3K/Akt Pathway Cross-ref Related
Protein-Protein Interaction Cross-ref Related Video
Companion Diagnostics Related Video